Bacteriophages as potential treatment for urinary tract infections

Frontiers in Microbiology

Volumn 7, Issue APR, 2016, Pages

  Sybesma, Wilbert ^a   Zbinden, Reinhard ^a   Chanishvili, Nino ^b   Kutateladze, Mzia ^b   Chkhotua, Archil ^c   Ujmajuridze, Aleksandre ^c   Mehnert, Ulrich ^a   Kessler, Thomas M ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Microbiology and Virology   (United States)

^c Tsulukidze National Center of Urology   (United States)

Author keywords

Antibiotic resistance; Antibiotics; Bacteriophage adaptation; Bacteriophages; Urinary tract infection

Indexed keywords

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIOPHAGE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GENETIC VARIABILITY; GENOTYPE; KLEBSIELLA PNEUMONIAE; MALE; MULTIPLE SCLEROSIS; PLAQUE ASSAY; PREVALENCE; PROSTATITIS; PUBLIC HEALTH; SCREENING TEST; URINARY TRACT INFECTION; VERTEBRAL CANAL STENOSIS;

EID: 84966320639     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2016.00465     Document Type: Article

References (29)

1. Abedon, S. T., Kuhl, S. J., Blasdel, B. G., and Kutter, E. M. (2011). Phage treatment of human infections. Bacteriophage 1, 66-85. doi: 10.4161/bact.1.2.15845.
2. Appelmans, R. (1921). Le dosage du bacteriophages. C. R. Soc. Biol. 85, 1098-1099.
3. Arshba, C., and Bagdoeva, K. (1965). Application of phage therapy against colibacterial infections of urinary tract. Clin. Exp. Urol. 3, 7-13.
4. Carlet, J., Collignon, P., Goldmann, D., Goossens, H., Gyssens, I. C., Harbarth, S., et al. (2011). Society's failure to protect a precious resource: antibiotics. Lancet 378, 369-371. doi: 10.1016/S0140-6736(11)60401-7.
5. Chanishvili, A. (2012). A Literature Review of the Practical Application of Bacteriophages. New York City: Nova Science Publishers.
6. Clokie, M. R. J., and Kropinski, A. (2009). Bacteriophages: Methods and Protocols. New York City: Humana Press.
7. Craigie, J., and Yen, C. H. (1938). The demonstration of types of B. typhosus by means of preparation of type II Vi phage. Can Public Health J. 29, 448-463.
8. Danilova, T. M. (1996). Phage therapy of the inflammatory urogenital infections in women. Proc. Dermatol. Venerol. 5:75.
9. Felix, A. (1956). Phage typing of Salmonella typhimurium: its place in epidemiological and epizootiological investigations. J. Gen. Microbiol. 14, 208-222. doi: 10.1099/00221287-14-1-208.
10. Felix, A., and Callow, B. R. (1943). Typing of paratyphoid B. Bacilli by Vi bacteriophage. Br. Med. J. 2, 127-130. doi: 10.1136/bmj.2.4308.127.
11. Fitzgerald-Hughes, D., Bolkvadze, D., Balarjishvili, N., Leshkasheli, L., Ryan, M., Burke, L., et al. (2014). Susceptibility of extended-spectrum-beta-lactamase-producing Escherichia coli to commercially available and laboratory-isolated bacteriophages. J. Antimicrob. Chemother. 69, 1148-1150. doi: 10.1093/jac/dkt453.
12. Foxman, B. (2002). Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am. J. Med. 113(Suppl. 1A), 5S-13S. doi: 10.1016/S0002-9343(02)01054-9.
13. Ghudumidze, N., Makalatia, K., Ediberidze, I., Kusradze, I., Karumidze, N., Merabishvili, M., et al. (2012). "Susceptibility of Salmonella and E. coli bacteriophages to environmental factors, " in Proceeding of the Conference: Bacteriophages and Probiotics-Alternatives to Antibiotics, Tbilisi.
14. Groen, J., Pannek, J., Castro Diaz, D., Del Popolo, G., Gross, T., Hamid, R., et al. (2016). Summary of European association of urology (EAU) guidelines on neuro-urology. Eur. Urol. 69, 324-333. doi: 10.1016/j.eururo.2015.07.071.
15. Karumidze, N., Kusradze, I., Rigvava, S., Goderdzishvili, M., Rajakumar, K., and Alavidze, Z. (2013). Isolation and characterisation of lytic bacteriophages of Klebsiella pneumoniae and Klebsiella oxytoca. Curr. Microbiol. 66, 251-258. doi: 10.1007/s00284-012-0264-7.
16. Khawaldeh, A., Morales, S., Dillon, B., Alavidze, Z., Ginn, A. N., Thomas, L., et al. (2011). Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. J. Med. Microbiol. 60, 1697-1700. doi: 10.1099/jmm.0.029744-0.
17. Khurtsia, N., Porchkhidze, K., Merabishvili, M., Tolordava, E., Burbutashvili, T., Giorkhelidze, T., et al. (2001). "Advances of clinical and theoretical Medicine and Biology, " Proceedings of the Conference Study of the Phage Susceptibility of the Strains Related to the Uro-Pathogenic E. coli and Enterococcus sp. Black-Sea Countries III International Conference, Tskaltubo.
18. Kolomeitsev, N. B., Goroeinko, I. I., Shakmatov, V. K., and Brazhnik, P. K. (1966). "Treatment of urological infections with different antibiotics and specific coli-proteus bacteriophages, " in Strategy and Tactics of Antibiotic Therapy (Krasnodar: Krasnodar Medical Institute), 172-174.
19. Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., et al. (2010). Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11, 69-86. doi: 10.2174/138920110790725401.
20. Letkiewicz, S., Miedzybrodzki, R., Klak, M., Jonczyk, E., Weber-Dabrowska, B., and Gorski, A. (2010). The perspectives of the application of phage therapy in chronic bacterial prostatitis. FEMS Immunol. Med. Microbiol. 60, 99-112. doi: 10.1111/j.1574-695X.2010.00723.x.
21. Mazzulli, T. (2002). Resistance trends in urinary tract pathogens and impact on management. J. Urol. 168, 1720-1722. doi: 10.1016/S0022-5347(05)64397-2.
22. Merabishvili, M., De Vos, D., Verbeken, G., Kropinski, A. M., Vandenheuvel, D., Lavigne, R., et al. (2012). Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany. PLoS ONE 7:e52709. doi: 10.1371/journal.pone.0052709.
23. Merabishvili, M., Vervaet, C., Pirnay, J. P., De Vos, D., Verbeken, G., Mast, J., et al. (2013). Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization). PLoS ONE 8:e68797. doi: 10.1371/journal.pone.0068797.
24. Perepanova, T. S., Debreeva, O. S., Koliatarova, G. A., Kondratieva, E. M., Aitskaia, I. M., Malysheva, V. T., et al. (1957). The efficacy of bacteriophages preparations in treatment of inflammatory urogenital diseases. Urol. Nephrol. 5, 14-17.
25. Pirnay, J. P., Blasdel, B. G., Bretaudeau, L., Buckling, A., Chanishvili, N., Clark, J. R., et al. (2015). Quality and safety requirements for sustainable phage therapy products. Pharm. Res. 32, 2173-2179. doi: 10.1007/s11095-014-1617-7.
26. Pirnay, J. P., De Vos, D., Verbeken, G., Merabishvili, M., Chanishvili, N., Vaneechoutte, M., et al. (2011). The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm Res. 28, 934-937. doi: 10.1007/s11095-010-0313-5.
27. Rüden, H., Gastmeier, P., Daschner, F. D., and Schumacher, M. (1997). Nosocomial and community-acquired infections in Germany. Summary of the results of the first national prevalence study (NIDEP). Infection 25, 199-202.
28. Samson, J. E., Magadan, A. H., Sabri, M., and Moineau, S. (2013). Revenge of the phages: defeating bacterial defences. Nat. Rev. Microbiol. 11, 675-687. doi: 10.1038/nrmicro3096.
29. Verbeken, G., Huys, I., Pirnay, J. P., Jennes, S., Chanishvili, N., Scheres, J., et al. (2014). Taking bacteriophage therapy seriously: a moral argument. Biomed. Res. Int. 2014:621316. doi: 10.1155/2014/621316.